The immunohistochemical analysis showed that the tumor regression strongly correlated with survivin expression in UFSHR-treated tumors derived from both PPCLs, compared to that in the vehicle or YM155 groups (Fig 5C). The gene discussed is BIRC5; the disease is neoplasm.